FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Olaratumab (Lartruvo) Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Eli Lilly and Co. (New 10/02/2019)

Company Contact Information:
800-545-5979

Presentation Posting Date Related Information
500mg/50 ML x 1 vial (NDC 0002-8926-01) 10/02/2019 Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.
190mg/19 ML x 1 vial (NDC 0002-7190-01) 10/02/2019 Market withdrawal of Lartruvo. There is no safety or quality issue related to the withdrawal.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English